Skip to main content

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-331

Product name
FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection
Sponsor name
Sanofi Aventis Australia Pty Ltd
Batches
UJ173AA
Consent start
Consent no.
CON-331
Standard
1. European Pharmacopeia (01/2019:0158). 2. Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines (TGO 91).
Non-compliance with standard
European Pharmacopeia (01/20190158) - passage level of three of the working seed lots is beyond the limit indicated in the standard (0158). The test for Bacterial Endotoxins (2.6.14) and the assay of Haemagglutinin Antigen by an immunodiffusion test (2.7.1) are not performed on the Final Lot. Therapeutic Goods Order No. 91 '“ Standard for labels of prescription and related medicines (TGO 91) - The batch is packaged in the Standard Export labelling (in Spanish and English), which does not conform with the requirements of TGO 91 on the following Paragraph 8(1)(d) the name of the dosage form (missing on carton) Paragraph 8(1)(i) the name and contact details of the sponsor (missing on carton) Subparagraph 8(1)(j)(iv)(A) indicating that the medicine contains the substance expressed using the Name stated in Column 4 of Schedule 1 (statement regarding manufactured in eggs missing on carton) Paragraph 9(1)(b) the name(s) of all active ingredients in the medicine (missing on syringe) Paragraph 9(1)(c) the quantity or proportion of all active ingredients in the medicine (missing on syringe) Subsection 9(3) the name of the medicine and the name of active ingredients on the main label (they are placed separately as the same texts in Spanish are placed before English texts) Paragraph 10(5)(c) the name of the medicine is displayed in a text size of not less than 1.5 millimetres (the trade name quot;FluQuadriquot; is less than 1.5 mm on syringe) Paragraph 11(1)(a) use of appropriate metric units (the abbreviation quot;mcgquot; is used rather than quot;microgramquot; in full on carton) Subsection 11(5) permitted statements of storage temperature conditions (quot;Store between +2ÌŠC to +8ÌŠC. Do not freezequot; is used rather than quot;Store at 2ÌŠC to 8ÌŠC Refrigerate. Do not freezequot; on carton).
Conditions imposed
          This consent applies only to the FluQuadri batch UJ173AA.        A 'Dear Healthcare Professional' letter identical to that provided to the TGA in the submission of the 27 May 2019 will be supplied with the affected batch.        Non-compliance with the European Pharmacopoeia is limited to the working seeds and tests detailed in the application submitted to the TGA on 27 May 2019.      
Therapeutic product type
Prescription medicines

Help us improve the Therapeutic Goods Administration site